Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, ImageneBio, Inc. reported revenue of $1M, down 77.1% year over year. Operating margin was -6056.4% and net margin -5668.6%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from IMA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1M | -6056.4% | -5668.6% |
| FY2024 | $4M | -1057.1% | -1044.8% |
| FY2023 | $9M | -823.3% | -744.2% |
| FY2022 | $16M | -454.0% | -440.3% |
| FY2021 | $31M | -110.2% | -110.1% |
How does IMA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.